查看购物车
  • Traditional Chinese
  • English
  • Japanese
北美基因分型市场预测至 2031 年 - 区域分析 - 按产品类型、技术、应用和最终用户
市场调查报告书
商品编码
1666233

北美基因分型市场预测至 2031 年 - 区域分析 - 按产品类型、技术、应用和最终用户

North America Genotyping Market Forecast to 2031 - Regional Analysis - by Product Type, Technology, Application, and End user
出版日期: | 出版商: The Insight Partners | 英文 147 Pages | 订单完成后即时交付

价格

2023 年北美基因分型市值为 120.4457 亿美元，预计到 2031 年将达到 629.0063 亿美元；预计 2023 年至 2031 年的复合年增长率为 23.0%。

遗传疾病和罕见疾病诊断应用推动北美基因分型市场发展

根据世界卫生组织 (WHO) 的数据，2050 年可能会出现约 3,500 万例新发癌症病例，比 2022 年的 2,000 万例增加 77%。这种疾病影响了超过600万各个年龄层的美国人。根据该协会的估计，截至 2022 年，650 万 65 岁以上的美国人患有阿兹海默症，其中 73% 年龄在 75 岁以上。根据《健康监测杂誌》发表的一项研究，全球有多达 3 亿人患有罕见疾病。儘管单一疾病很罕见，但它们共同为全球医疗保健系统带来了重大挑战。

由于癌症、阿兹海默症和罕见疾病在临床上难以识别，基因分型成为族群诊断检测的支柱。可以将从基因分型获得的 DNA 序列与样本或参考序列进行比较以确定变异。基因分型也用于检测单核苷酸多态性（SNP），即群体内遗传互补的微小变异。人类基因组拥有近6.6亿个SNP，这是最常见的遗传变异。此外，透过比较健康和患病人群的多态性，全基因组关联研究 (GWAS) 可以揭示常见疾病与 SNP 之间的关联。 GWAS 可以透过寻找可能的原因来解开潜在疾病状态的分子机制。 SNP 甚至存在于单细胞生物中，例如细菌。 SNP 基因分型可以区分微生物分离株，甚至可以用于识别抗生素抗药性菌株。基于SNP的菌株检测对各个药物和临床分析都有重大的影响，在传染病流行病学中也得到了应用。

北美基因分型市场概览

北美基因分型市场分为美国、加拿大和墨西哥。越来越多地采用技术先进的产品和解决方案以及不断涌现的研究和开发活动是该地区基因分型市场受益的因素。此外，政府主导的计画（例如「我们所有人的研究计画」）、各个基因组学界发起的倡议以及人们对基因分型服务的日益认识是推动北美市场扩张的主要驱动力。

北美基因分型市场收入及预测（百万美元）

北美基因分型市场细分

北美基因分型市场分为产品类型、技术、应用、最终用户和国家。

根据产品类型，北美基因分型市场分为仪器、试剂和试剂盒、生物资讯学和基因分型服务。试剂和试剂盒部分在 2023 年占据了最大的市场份额。

根据技术，北美基因分型市场分为微阵列、毛细管电泳、定序、聚合酶炼式反应（PCR）、基质辅助雷射解吸/MALDI-TOF 和其他技术。聚合酶链反应 (PCR) 领域在 2023 年占据了最大的市场份额。

根据应用，北美基因分型市场细分为药物基因组学、诊断和个人化医疗、动物遗传学、农业生物技术和其他应用。 2023 年，诊断和个人化医疗领域占据最大的市场份额。

就最终用户而言，北美基因分型市场分为製药和生物製药公司、诊断和研究实验室、学术机构和其他最终用户。 2023 年，製药和生物製药公司部门占据了最大的市场份额。

依国家划分，北美基因分型市场分为美国、加拿大和墨西哥。 2023 年美国占据北美基因分型市场的主导份额。

Hoffmann-La Roche Ltd、QIAGEN NV、Merck KGaA、Thermo Fisher Scientific Inc、BioTek Instruments, Inc、TRIMGEN CORPORATION、Illumina Inc、Danaher Corp、Bio-Rad Laboratories Inc、GE HealthCare Technologies Inc、Standard BioTools Inc、Laboratory Corp of America、Sooratory Corp.是北美基因分型市场的一些领导公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 发育基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：北美基因分型市场格局

  • 概述
  • PEST分析
  • 全球市占率分析
    • NGS 文库製备主要参与者的全球市占率（%）
    • 基因分型领导企业的全球市场占有率（%）
    • 基因表现领域领导企业的全球市场占有率（%）

第 5 章：北美基因分型市场 - 主要市场动态

  • 市场驱动因素：
    • 用于诊断遗传疾病和罕见疾病
    • 生物技术和製药行业的技术进步和研发投资不断增加
  • 市场限制
    • 设备成本高，专业技术人员短缺
  • 市场机会
    • 扩大应用范围
  • 未来趋势
    • 个人化医疗日益普及
  • 驱动因素和限制因素的影响：

第 6 章：基因分型市场 - 北美分析

  • 2021 至 2031 年基因分型市场收入

第 7 章：北美基因分型市场分析 - 依产品类型

  • 仪器
  • 试剂和试剂盒
  • 生物资讯学
  • 基因分型服务

第 8 章：北美基因分型市场分析 - 按技术

  • 微阵列
  • 毛细管电泳
  • 定序
  • 聚合酶炼式反应（PCR）
  • 基质辅助雷射解吸/MALDI-TOF
  • 其他技术

第 9 章：北美基因分型市场分析 - 按应用

  • 药物基因组学
  • 诊断及个人化医疗
  • 动物遗传学
  • 农业生物技术
  • 其他应用

第 10 章：北美基因分型市场分析 - 按最终用户

  • 製药和生物製药公司
  • 诊断与研究实验室
  • 学术机构
  • 其他最终用户

第 11 章：北美基因分型市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 12 章：产业格局

  • 概述
  • 基因分型市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 13 章：公司简介

  • Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Merck KGaA
  • Thermo Fisher Scientific Inc
  • BioTek Instruments, Inc.
  • TRIMGEN CORPORATION
  • Illumina Inc
  • Danaher Corp
  • Bio-Rad Laboratories Inc
  • GE HealthCare Technologies Inc
  • Standard BioTools Inc
  • Laboratory Corp of America Holdings
  • Beckman Coulter Inc
  • BGI
  • Takara Bio Inc
  • DiaSorin SpA

第 14 章：附录

Product Code: BMIRE00025971

The North America genotyping market was valued at US$ 12,044.57 million in 2023 and is expected to reach US$ 62,900.63 million by 2031; it is estimated to record a CAGR of 23.0% from 2023 to 2031.

Use in Diagnosis of Genetic and Rare Diseases Fuels North America Genotyping Market

According to the World Health Organization (WHO), ~35 million new cancer cases are likely to occur in 2050, a 77% increase from the corresponding 20 million cases in 2022. In 2022, the Alzheimer's Association stated that the number of people living with Alzheimer's in the US is rapidly increasing. The disease affects more than 6 million Americans from all age groups. As per the association's estimates, 6.5 million Americans aged more than 65 suffered from Alzheimer's as of 2022, and 73% of this population was aged 75 or older. As per a study published in the Journal of Health Monitoring, up to 300 million people worldwide suffer from rare diseases. Although individual diseases are rare, they collectively pose significant challenges to the global healthcare system.

Since cancer, Alzheimer's disease, and rare diseases are difficult to identify clinically, genotyping stands as the backbone of diagnostic testing in the population. DNA sequences obtained from genotyping can be compared to sample or reference sequences to determine variations. Genotyping is also employed to detect single-nucleotide polymorphisms (SNPs), which are minor variations in genetic complement within the population. The human genome has nearly 660 million SNPs, which makes them the most widespread genetic variation. Moreover, by comparing polymorphisms in healthy and diseased populations, genome-wide association studies (GWAS) can uncover links between common illnesses and SNPs. GWAS can untangle the molecular mechanisms in underlying disease states by finding probable causes. SNPs are even present in single-celled organisms, such as bacteria. SNP genotyping can discriminate between microorganism isolates and could even be accustomed to identifying antibiotic-resistant strains. SNP-based strain detection has a significant impact on each pharmaceutical and clinical analysis, and it has also been used in infectious disease epidemiology.

North America Genotyping Market Overview

The North America genotyping market is segmented into the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging research and development activities are the factors benefiting the genotyping market in this region. Moreover, government-led programs such as the "All of Us Research Program," initiatives by various genomic communities, and the increasing awareness of genotyping services are the key drivers of the market expansion across North America.

North America Genotyping Market Revenue and Forecast to 2031 (US$ Million)

North America Genotyping Market Segmentation

The North America genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the North America genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the North America genotyping market is categorized into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the North America genotyping market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the North America genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the North America genotyping market is segmented into the US, Canada, and Mexico. The US dominated the North America genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments, Inc, TRIMGEN CORPORATION, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the North America genotyping market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Genotyping Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Global Market Share Analysis
    • 4.3.1 Global Market Share (%) of Leading Players for NGS Library Preparation
    • 4.3.2 Global Market Share (%) of Leading Player for Genotyping
    • 4.3.3 Global Market Share (%) of Leading Player for Gene Expression

5. North America Genotyping Market - Key Market Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
    • 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
  • 5.3 Market Opportunities
    • 5.3.1 Expanding Range of Applications
  • 5.4 Future Trends
    • 5.4.1 Increasing Popularity of Personalized Medicine
  • 5.5 Impact of Drivers and Restraints:

6. Genotyping Market - North America Analysis

  • 6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. North America Genotyping Market Analysis - by Product Type

  • 7.1 Instruments
    • 7.1.1 Overview
    • 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Reagents and Kits
    • 7.2.1 Overview
    • 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Bioinformatics
    • 7.3.1 Overview
    • 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Genotyping Services
    • 7.4.1 Overview
    • 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Genotyping Market Analysis - by Technology

  • 8.1 Microarray
    • 8.1.1 Overview
    • 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Capillary Electrophoresis
    • 8.2.1 Overview
    • 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Sequencing
    • 8.3.1 Overview
    • 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Polymerase Chain Reaction (PCR)
    • 8.4.1 Overview
    • 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
    • 8.5.1 Overview
    • 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Other Technologies
    • 8.6.1 Overview
    • 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Genotyping Market Analysis - by Application

  • 9.1 Pharmacogenomics
    • 9.1.1 Overview
    • 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Diagnostics and Personalized Medicine
    • 9.2.1 Overview
    • 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Animal Genetics
    • 9.3.1 Overview
    • 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Agricultural Biotechnology
    • 9.4.1 Overview
    • 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Other Applications
    • 9.5.1 Overview
    • 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Genotyping Market Analysis - by End-user

  • 10.1 Pharmaceutical and Biopharmaceutical Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Overview
    • 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Academic Institutes
    • 10.3.1 Overview
    • 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Other End Users
    • 10.4.1 Overview
    • 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Genotyping Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America: Genotyping Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 United States: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.1 United States: Genotyping Market Breakdown, by Product Type
        • 11.1.1.1.2 United States: Genotyping Market Breakdown, by Technology
        • 11.1.1.1.3 United States: Genotyping Market Breakdown, by Application
        • 11.1.1.1.4 United States: Genotyping Market Breakdown, by End-user
      • 11.1.1.2 Canada: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.1 Canada: Genotyping Market Breakdown, by Product Type
        • 11.1.1.2.2 Canada: Genotyping Market Breakdown, by Technology
        • 11.1.1.2.3 Canada: Genotyping Market Breakdown, by Application
        • 11.1.1.2.4 Canada: Genotyping Market Breakdown, by End-user
      • 11.1.1.3 Mexico: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.1 Mexico: Genotyping Market Breakdown, by Product Type
        • 11.1.1.3.2 Mexico: Genotyping Market Breakdown, by Technology
        • 11.1.1.3.3 Mexico: Genotyping Market Breakdown, by Application
        • 11.1.1.3.4 Mexico: Genotyping Market Breakdown, by End-user

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Genotyping Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 QIAGEN NV
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Merck KGaA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Thermo Fisher Scientific Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 BioTek Instruments, Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 TRIMGEN CORPORATION
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Illumina Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Danaher Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bio-Rad Laboratories Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 GE HealthCare Technologies Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Standard BioTools Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 Laboratory Corp of America Holdings
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Beckman Coulter Inc
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 BGI
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Takara Bio Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments
  • 13.16 DiaSorin SpA
    • 13.16.1 Key Facts
    • 13.16.2 Business Description
    • 13.16.3 Products and Services
    • 13.16.4 Financial Overview
    • 13.16.5 SWOT Analysis
    • 13.16.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Genotyping Market Segmentation
  • Table 2. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 3. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 4. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 5. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by End-user
  • Table 6. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 7. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 8. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 9. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 10. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 11. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 12. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 13. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 14. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 15. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 16. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 17. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 18. Recent Organic Growth Strategies in Genotyping Market
  • Table 19. Recent Inorganic Growth Strategies in the Genotyping Market
  • Table 20. Glossary of Terms, Genotyping Market

List Of Figures

  • Figure 1. North America Genotyping Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Genotyping Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Genotyping Market Revenue (US$ Million), 2021-2031
  • Figure 6. Genotyping Market Share (%) - by Product Type (2023 and 2031)
  • Figure 7. Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Genotyping Market Share (%) - by Technology (2023 and 2031)
  • Figure 12. Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Genotyping Market Share (%) - by Application (2023 and 2031)
  • Figure 19. Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Genotyping Market Share (%) - by End-user (2023 and 2031)
  • Figure 25. Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America Genotyping Market, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 30. North America: Genotyping Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 31. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Growth Strategies in Genotyping Market